A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
Latest Information Update: 07 Mar 2024
At a glance
- Drugs OQL 011 (Primary)
- Indications Erythrodysaesthesia; Skin disorders
- Focus Proof of concept; Therapeutic Use
- Acronyms NOVA-II
- Sponsors OnQuality Pharmaceuticals
Most Recent Events
- 01 Mar 2024 Planned End Date changed from 1 Mar 2024 to 1 Jun 2024.
- 01 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 06 Apr 2023 Planned End Date changed from 1 Oct 2023 to 1 Mar 2024.